Topic:

Emerging Markets

Latest Headlines

Latest Headlines

India's IP stance in focus as TPP talks on drug trade policy drag on

When the just-ended New York negotiations failed to resolve drug-patenting and other intellectual property issues, the focus shifted to a ministerial-level meeting of the Trans-Pacific Partnership expected to take place in March. 

India jumps into the generic drug biz to compete with commercial players on price

SINGAPORE-- India's government is getting into the generic drug business. The state reportedly will launch its own brand, "Jan Aushadhi," on July 1, planning to sell up to 504 drugs on its "essential" list in direct competition with commercial drugmakers.

Sanofi ups diabetes game in India through hospital clinics, local production

France's Sanofi has taken dramatic steps to increase its diabetes-related presence in India with shades of Viehbacher plans.

New Gilead patent challenger pops up as Delhi court forces a rehearing

SINGAPORE-- As soon as the Delhi High Court revived Gilead Sciences' patent hopes for Sovaldi, a new actor has come on the scene: Sankalp Rehabilitation Trust, which has joined three other plaintiffs in opposing the new patent.

Dr. Reddy's mulling facility shift to avoid losing out on Nexium generic

Dr. Reddy's Laboratories is weighing a shift away from its Srikakulam facility in southern India where some of its key active pharmaceutical ingredients are produced and which is under an FDA investigation.

Emerging market demand saves Irish Lipitor plant from closing

A Pfizer plant in Ireland that was slated to close last year is still running strong, as sales of blockbuster cholesterol drug Lipitor remain vibrant in some parts of the world three years after losing its U.S. patent.

Drugmakers look to India for drug safety monitoring

India has long been a major player in the development and manufacturing of treatments, but more and more drugmakers are outsourcing the monitoring of on-the-market drugs to vendors in the country.

UPDATED: Mylan's women's health biz leaps to fore in emerging markets with $750M Famy deal

Mylan will pay $750 million in cash to buy the women's healthcare businesses from India's Famy Care, placing it as the top seller of contraceptives in emerging markets.

Chinese square off against Alibaba in palace intrigue as online drug sales loom

Who knew that China FDA's planned lifting of a ban on online drug sales meant the global pharmaceutical industry could become a subject of a Chinese version of palace intrigue?

Amid new drug negotiations, China puts price-management vet in charge of CFDA

SINGAPORE-- A change in leadership at the China Drug and Food Administration was announced on the Communist Party website last week: Bi Jingquan, who has more than 20 years of experience in pricing and management, will take over from Zhang Yong as CFDA minister.